nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.02.2014 | Review Article

Ischaemic memory imaging using metabolic radiopharmaceuticals: overview of clinical settings and ongoing investigations

verfasst von: Keiichiro Yoshinaga, Masanao Naya, Tohru Shiga, Eriko Suzuki, Nagara Tamaki

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

“Ischaemic memory” is defined as a prolonged functional and/or biochemical alteration remaining after a particular episode of severe myocardial ischaemia. The biochemical alteration has been reported as metabolic stunning. Metabolic imaging has been used to detect the footprint left by previous ischaemic episodes evident due to delayed recovery of myocardial metabolism (persistent dominant glucose utilization with suppression of fatty acid oxidation). β-Methyl-p-[¹²³I]iodophenylpentadecanoic acid (BMIPP) is a single-photon emission computed tomography (SPECT) radiotracer widely used for metabolic imaging in clinical settings in Japan. In patients with suspected coronary artery disease but no previous myocardial infarction, BMIPP has shown acceptable diagnostic accuracy. In particular, BMIPP plays an important role in the identification of prior ischaemic insult in patients arriving at emergency departments with acute chest pain syndrome. Recent data also show the usefulness of ¹²³I-BMIPP SPECT for predicting cardiovascular events in patients undergoing haemodialysis. Similarly, SPECT or PET imaging with ¹⁸F-FDG injected during peak exercise or after exercise under fasting conditions shows an increase in FDG uptake in postischaemic areas. This article will overview the roles of ischaemic memory imaging both under established indications and in ongoing investigations.

Fallavollita JA, Malm BJ, Canty Jr JM. Hibernating myocardium retains metabolic and contractile reserve despite regional reductions in flow, function, and oxygen consumption at rest. Circ Res. 2003;92:48–55.PubMedCrossRef

Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982;66:1146–9.PubMedCrossRef

Bolli R. Mechanism of myocardial “stunning”. Circulation. 1990;82:723–38.PubMedCrossRef

Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation. 2001;104:3158–67.PubMedCrossRef

Villanueva FS, Lu E, Bowry S, Kilic S, Tom E, Wang J, et al. Myocardial ischemic memory imaging with molecular echocardiography. Circulation. 2007;115:345–52.PubMedCrossRef

Dilsizian V. Metabolic adaptation to myocardial ischemia: the role of fatty acid imaging. J Nucl Cardiol. 2007;14:S97–9.PubMedCrossRef

Tamaki N, Morita K, Kuge Y, Tsukamoto E. The role of fatty acids in cardiac imaging. J Nucl Med. 2000;41:1525–34.PubMed

Yoshinaga K, Tamaki N. Imaging myocardial metabolism. Curr Opin Biotechnol. 2007;18:52–9.PubMedCrossRef

Tamaki N, Yoshinaga K. Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology. J Nucl Cardiol. 2011;18:135–43.PubMedCrossRefPubMedCentral

10.

Kosnik JW, Zalenski RJ, Shamsa F, Harris R, Mittner J, Kozlowski J, et al. Resting sestamibi imaging for the prognosis of low-risk chest pain. Acad Emerg Med. 1999;6:998–1004.PubMedCrossRef

11.

Udelson JE, Beshansky JR, Ballin DS, Feldman JA, Griffith JL, Handler J, et al. Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. JAMA. 2002;288:2693–700.PubMedCrossRef

12.

Asanuma T, Uranishi A, Masuda K, Ishikura F, Beppu S, Nakatani S. Assessment of myocardial ischemic memory using persistence of post-systolic thickening after recovery from ischemia. JACC Cardiovasc Imaging. 2009;2:1253–61.PubMedCrossRef

13.

Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation. 2008;117:103–14.PubMedCrossRef

14.

Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis. 1981;23:321–36.PubMedCrossRef

15.

Taegtmeyer H, Woods A. Clinical trials report. Metabolic modulation as a principle for myocardial protection. Curr Hypertens Rep. 2003;5:443–4.PubMedCrossRef

16.

Schelbert HR, Henze E, Phelps ME, Kuhl DE. Assessment of regional myocardial ischemia by positron-emission computed tomography. Am Heart J. 1982;103:588–97.PubMedCrossRef

17.

Schwaiger M, Schelbert HR, Ellison D, Hansen H, Yeatman L, Vinten-Johansen J, et al. Sustained regional abnormalities in cardiac metabolism after transient ischemia in the chronic dog model. J Am Coll Cardiol. 1985;6:336–47.PubMedCrossRef

18.

Schwaiger M, Neese RA, Araujo L, Wyns W, Wisneski JA, Sochor H, et al. Sustained nonoxidative glucose utilization and depletion of glycogen in reperfused canine myocardium. J Am Coll Cardiol. 1989;13:745–54.PubMedCrossRef

19.

Taegtmeyer H, Dilsizian V. Imaging myocardial metabolism and ischemic memory. Nat Clin Pract Cardiovasc Med. 2008;5 Suppl 2:S42–8.PubMedCrossRef

20.

Tamaki N, Tadamura E, Kudoh T, Hattori N, Inubushi M, Konishi J. Recent advances in nuclear cardiology in the study of coronary artery disease. Ann Nucl Med. 1997;11:55–66.PubMedCrossRef

21.

Kawai Y, Tsukamoto E, Nozaki Y, Morita K, Sakurai M, Tamaki N. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol. 2001;38:1888–94.PubMedCrossRef

22.

Tamaki N, Morita K, Kawai Y. The Japanese experience with metabolic imaging in the clinical setting. J Nucl Cardiol. 2007;14:S145–52.PubMedCrossRef

23.

Dilsizian V, Bateman TM, Bergmann SR, Des Prez R, Magram MY, Goodbody AE, et al. Metabolic imaging with beta-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation. 2005;112:2169–74.PubMedCrossRef

24.

Camici PG. Myocardial ischaemia and metabolic memory. Eur J Nucl Med Mol Imaging. 2006;33:4–5.PubMedCrossRef

25.

Knapp Jr FF, Kropp J. Iodine-123-labelled fatty acids for myocardial single-photon emission tomography: current status and future perspectives. Eur J Nucl Med. 1995;22:361–81.PubMedCrossRef

26.

Yamamichi Y, Kusuoka H, Morishita K, Shirakami Y, Kurami M, Okano K, et al. Metabolism of iodine-123-BMIPP in perfused rat hearts. J Nucl Med. 1995;36:1043–50PubMed

27.

Hosokawa R, Nohara R, Fujibayashi Y, Okuda K, Ogino M, Hirai T, et al. Myocardial metabolism of 123I-BMIPP in a canine model with ischemia: implications of perfusion-metabolism mismatch on SPECT images in patients with ischemic heart disease. J Nucl Med. 1999;40:471–8.PubMed

28.

Fujibayashi Y, Nohara R, Hosokawa R, Okuda K, Yonekura Y, Tamaki N, et al. Metabolism and kinetics of iodine-123-BMIPP in canine myocardium. J Nucl Med. 1996;37:757–61.PubMed

29.

Thompson RC, Cullom SJ. Issues regarding radiation dosage of cardiac nuclear and radiography procedures. J Nucl Cardiol. 2006;13:19–23.PubMedCrossRef

30.

Inaba Y, Bergmann SR. Diagnostic accuracy of beta-methyl-p-[123I]-iodophenyl-pentadecanoic acid (BMIPP) imaging: a meta-analysis. J Nucl Cardiol. 2008;15:345–52.PubMedCrossRef

31.

Matsuo S, Nakajima K, Yamashina S, Sakata K, Momose M, Hashimoto J, et al. Characterization of Japanese standards for myocardial sympathetic and metabolic imaging in comparison with perfusion imaging. Ann Nucl Med. 2009;23:517–22.PubMedCrossRef

32.

Yoshinaga K, Matsuki T, Hashimoto A, Tsukamoto K, Nakata T, Tamaki N. Validation of automated quantitation of myocardial perfusion and fatty acid metabolism abnormalities on SPECT images. Circ J. 2011;75:2187–95.PubMedCrossRef

33.

Nohara R, Hosokawa R, Hirai T, Okuda K, Ogino M, Fujibayashi Y, et al. Effect of metabolic substrate on BMIPP metabolism in canine myocardium. J Nucl Med. 1998;39:1132–7.PubMed

34.

Kataoka K, Nohara R, Hosokawa R, Hirai T, Okuda K, Li-Guang C, et al. Myocardial lipid metabolism in compensated and advanced stages of heart failure: evaluation by canine pacing model with BMIPP. J Nucl Med. 2001;42:124–9.PubMed

35.

Hosokawa R, Nohara R, Fujibayashi Y, Okuda K, Ogino M, Hata T, et al. Myocardial kinetics of iodine-123-BMIPP in canine myocardium after regional ischemia and reperfusion: implications for clinical SPECT. J Nucl Med. 1997;38:1857–63.PubMed

36.

Ito K, Sugihara H, Kawasaki T, Katoh S, Azuma A, Nakagawa M. Dynamic changes in cardiac fatty acid metabolism in the stunned human myocardium. Ann Nucl Med. 2001;15:343–50.PubMedCrossRef

37.

Kageyama H, Morita K, Katoh C, Tsukamoto T, Noriyasu K, Mabuchi M, et al. Reduced 123I-BMIPP uptake implies decreased myocardial flow reserve in patients with chronic stable angina. Eur J Nucl Med Mol Imaging. 2006;33:6–12.PubMedCrossRef

38.

Morimoto K, Tomoda H, Yoshitake M, Aoki N, Handa S, Suzuki Y. Prediction of coronary artery lesions in unstable angina by iodine 123 beta-methyl iodophenyl pentadecanoic acid (BMIPP), a fatty acid analogue, single photon emission computed tomography at rest. Angiology. 1999;50:639–48.PubMedCrossRef

39.

Suzuki A, Takada Y, Nagasaka M, Kato R, Watanabe T, Shimokata K, et al. Comparison of resting beta-methyl-iodophenyl pentadecanoic acid (BMIPP) and thallium-201 tomography using quantitative polar maps in patients with unstable angina. Jpn Circ J. 1997;61:133–8.PubMedCrossRef

40.

Kontos MC, Dilsizian V, Weiland F, DePuey G, Mahmarian JJ, Iskandrian AE, et al. Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes: a multicenter trial. J Am Coll Cardiol. 2010;56:290–9.PubMedCrossRef

41.

Iwado H, Iwado Y, Ohmori K, Mizushige K, Yukiiri K, Takagi Y, et al. Latent abnormal fatty acid metabolism in apparently normal perfusion during stress in patients with restenosis after coronary angioplasty: assessment by exercise stress thallium-201 and iodine-123-labeled 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid-dual myocardial single-photon emission computed tomography. Am J Cardiol. 2004;93:685–8.PubMedCrossRef

42.

Hatano T, Chikamori T, Usui Y, Morishima T, Hida S, Yamashina A. Diagnostic significance of positive I-123 BMIPP despite negative stress Tl-201 myocardial imaging in patients with suspected coronary artery disease. Circ J. 2006;70:184–9.PubMedCrossRef

43.

Yamabe H, Fujiwara S, Rin K, Ando M, Yokoyama M, Sakamoro T, et al. Resting 123I-BMIPP scintigraphy for detection of organic coronary stenosis and therapeutic outcome in patients with chest pain. Ann Nucl Med. 2000;14:187–92.PubMedCrossRef

44.

Nakajima K, Shimizu K, Taki J, Uetani Y, Konishi S, Tonami N, et al. Utility of iodine-123-BMIPP in the diagnosis and follow-up of vasospastic angina. J Nucl Med. 1995;36:1934–40.PubMed

45.

Watanabe K, Ohta Y, Toba K, Ogawa Y, Aizawa Y, Tanabe N, et al. Abnormal fatty acid metabolism in patients with coronary vasospasm. Ann Nucl Med. 1999;13:33–41.PubMedCrossRef

46.

Watanabe K, Takahashi T, Miyajima S, Hirokawa Y, Tanabe N, Kato K, et al. Myocardial sympathetic denervation, fatty acid metabolism, and left ventricular wall motion in vasospastic angina. J Nucl Med. 2002;43:1476–81.PubMed

47.

Kawai Y, Morita K, Nozaki Y, Ohkusa T, Sakurai M, Tamaki N. Diagnostic value of 123I-betamethyl-p-iodophenyl-pentadecanoic acid (BMIPP) single photon emission computed tomography (SPECT) in patients with chest pain. Comparison with rest-stress 99mTc-tetrofosmin SPECT and coronary angiography. Circ J. 2004;68:547–52.PubMedCrossRef

48.

Matsuki T, Tamaki N, Nakata T, Doi A, Takahashi H, Iwata M, et al. Prognostic value of fatty acid imaging in patients with angina pectoris without prior myocardial infarction: comparison with stress thallium imaging. Eur J Nucl Med Mol Imaging. 2004;31:1585–91.PubMedCrossRef

49.

Chikamori T, Fujita H, Nanasato M, Toba M, Nishimura T. Prognostic value of I-123 15-(p-iodophenyl)-3-(R, S) methylpentadecanoic acid myocardial imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol. 2005;12:172–8.PubMedCrossRef

50.

Nakata T, Hashimoto A, Matsuki T, Yoshinaga K, Tsukamoto K, Tamaki N. Prognostic value of automated SPECT scoring system for coronary artery disease in stress myocardial perfusion and fatty acid metabolism imaging. Int J Cardiovasc Imaging. 2013;29:253–62.PubMedCrossRefPubMedCentral

51.

Momose M, Miyake Y, Fukushima K, Nakajima T, Kondo C, Hagiwara N, et al. Prognostic value of (123)I-betamethyl-p-iodophenyl-pentadecanoic acid single-photon emission computed tomography in diabetic patients with suspected ischemic heart disease. Circ J. 2012;76:2633–9.PubMedCrossRef

52.

JCS Working Group; Tamaki N, Kumita S, Kusakabe K, Matsuzaki M, Nishimura T, Senda S, et al. Guidelines for clinical use of cardiac nuclear medicine (JCS 2010) – digest version. Circ J. 2012;76:761–7.CrossRef

53.

Takeishi Y, Fujiwara S, Atsumi H, Takahashi K, Sukekawa H, Tomoike H. Iodine-123-BMIPP imaging in unstable angina: a guide for interventional strategy. J Nucl Med. 1997;38:1407–11.PubMed

54.

Fujiwara S, Takeishi Y, Atsumi H, Takahashi K, Tomoike H. Fatty acid metabolic imaging with iodine-123-BMIPP for the diagnosis of coronary artery disease. J Nucl Med. 1997;38:175–80.PubMed

55.

Tateno M, Tamaki N, Yukihiro M, Kudoh T, Hattori N, Tadamura E, et al. Assessment of fatty acid uptake in ischemic heart disease without myocardial infarction. J Nucl Med. 1996;37:1981–5.PubMed

56.

Nishimura M, Hashimoto T, Kobayashi H, Fukuda T, Okino K, Yamamoto N, et al. Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients. Kidney Int. 2004;66:811–9.PubMedCrossRef

57.

Nishimura M, Tsukamoto K, Tamaki N, Kikuchi K, Iwamoto N, Ono T. Risk stratification for cardiac death in hemodialysis patients without obstructive coronary artery disease. Kidney Int. 2011;79:363–71.PubMedCrossRef

58.

Nishimura M, Tsukamoto K, Hasebe N, Tamaki N, Kikuchi K, Ono T. Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol. 2008;51:139–45.PubMedCrossRef

59.

Moroi M, Tamaki N, Nishimura M, Haze K, Nishimura T, Kusano E, et al. Association between abnormal myocardial fatty acid metabolism and cardiac-derived death among patients undergoing hemodialysis: results from a cohort study in Japan. Am J Kidney Dis. 2013;61:466–75.PubMedCrossRef

60.

Hirakata H, Nitta K, Inaba M, Shoji T, Fujii H, Kobayashi S, et al. Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther Apher Dial. 2012;16:387–435.PubMedCrossRef

61.

Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314:884–8.PubMedCrossRef

62.

Tamaki N, Kawamoto M, Tadamura E, Magata Y, Yonekura Y, Nohara R, et al. Prediction of reversible ischemia after revascularization. Perfusion and metabolic studies with positron emission tomography. Circulation. 1995;91:1697–705.PubMedCrossRef

63.

Yoshinaga K, Manabe O, Tamaki N. Physiological assessment of myocardial perfusion using nuclear cardiology would enhance coronary artery disease patient care: which imaging modality is best for evaluation of myocardial ischemia? (SPECT-side). Circ J. 2011;75:713–22; discussion 31.PubMedCrossRef

64.

Schelbert HR. 18F-deoxyglucose and the assessment of myocardial viability. Semin Nucl Med. 2002;32:60–9.PubMedCrossRef

65.

Machac J, Bacharach SL, Bateman TM, Bax JJ, Beanlands R, Bengel F, et al. Positron emission tomography myocardial perfusion and glucose metabolism imaging. J Nucl Cardiol. 2006;13:e121–51.PubMedCrossRef

66.

Camici P, Araujo LI, Spinks T, Lammertsma AA, Kaski JC, Shea MJ, et al. Increased uptake of 18F-fluorodeoxyglucose in postischemic myocardium of patients with exercise-induced angina. Circulation. 1986;74:81–8.PubMedCrossRef

67.

McFalls EO, Murad B, Liow JS, Gannon MC, Haspel HC, Lange A, et al. Glucose uptake and glycogen levels are increased in pig heart after repetitive ischemia. Am J Physiol Heart Circ Physiol. 2002;282:H205–11.PubMed

68.

Camici P, Ferrannini E, Opie LH. Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis. 1989;32:217–38.PubMedCrossRef

69.

McNulty PH, Jagasia D, Cline GW, Ng CK, Whiting JM, Garg P, et al. Persistent changes in myocardial glucose metabolism in vivo during reperfusion of a limited-duration coronary occlusion. Circulation. 2000;101:917–22.PubMedCrossRef

70.

Araujo LI, McFalls EO, Lammertsma AA, Jones T, Maseri A. Dipyridamole-induced increased glucose uptake in patients with single-vessel coronary artery disease assessed with PET. J Nucl Cardiol. 2001;8:339–46.PubMedCrossRef

71.

Dilsizian V. 18F-FDG uptake as a surrogate marker for antecedent ischemia. J Nucl Med. 2008;49:1909–11.PubMedCrossRef

72.

He ZX, Shi RF, Wu YJ, Tian YQ, Liu XJ, Wang SW, et al. Direct imaging of exercise-induced myocardial ischemia with fluorine-18-labeled deoxyglucose and Tc-99m-sestamibi in coronary artery disease. Circulation. 2003;108:1208–13.PubMedCrossRef

73.

Dou KF, Yang MF, Yang YJ, Jain D, He ZX. Myocardial 18F-FDG uptake after exercise-induced myocardial ischemia in patients with coronary artery disease. J Nucl Med. 2008;49:1986–91.PubMedCrossRef

74.

Fink JC, Lodge MA, Smith MF, Hinduja A, Brown J, Dinits-Pensy MY, et al. Pre-clinical myocardial metabolic alterations in chronic kidney disease. Cardiology. 2010;116:160–7.PubMedCrossRef

75.

Gropler RJ, Siegel BA, Lee KJ, Moerlein SM, Perry DJ, Bergmann SR, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med. 1990;31:1749–56.PubMed

76.

Ohira H, Tsujino I, Yoshinaga K. 18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2011;38:1773–83.PubMedCrossRef

Titel: Ischaemic memory imaging using metabolic radiopharmaceuticals: overview of clinical settings and ongoing investigations
verfasst von: Keiichiro Yoshinaga
Masanao Naya
Tohru Shiga
Eriko Suzuki
Nagara Tamaki
Publikationsdatum: 01.02.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2615-4

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Feasibility of temporary protective embolization of normal liver tissue using degradable starch microspheres during radioembolization of liver tumours

Good clinical practice in pulmonary embolism diagnosis: where do we stand today?

Erratum to: Twins in spirit: DOTATATE and high-affinity DOTATATE

Improving the dose–myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP

High-resolution imaging of pulmonary ventilation and perfusion with 68Ga-VQ respiratory gated (4-D) PET/CT

Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels